Philip E Lammers Christine M Lovly Leora Horn
10.6004/jnccn.2014.0002
J Natl Compr Canc Netw
2014 Jan;12(1):6-11; quiz 11.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/24453288/
Adenocarcinoma / genetics Carcinoma, Non-Small-Cell Lung / genetics ErbB Receptors / genetics Lung Neoplasms / genetics Phosphatidylinositol 3-Kinases / genetics
Adenocarcinoma / genetics Carcinoma, Non-Small-Cell Lung / genetics ErbB Receptors / genetics Lung Neoplasms / genetics Phosphatidylinositol 3-Kinases / genetics Case Reports Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Adenocarcinoma / drug therapy Adenocarcinoma / pathology Adenocarcinoma of Lung Aged Carcinoma, Non-Small-Cell Lung / drug therapy Class I Phosphatidylinositol 3-Kinases Crizotinib Drug Resistance, Neoplasm / genetics Erlotinib Hydrochloride Humans Lung Neoplasms / drug therapy Lung Neoplasms / pathology Male Mutation Precision Medicine Pyrazoles / administration & dosage Pyridines / administration & dosage Quinazolines / administration & dosage Treatment Outcome Pyrazoles Pyridines Quinazolines Crizotinib Erlotinib Hydrochloride Phosphatidylinositol 3-Kinases Class I Phosphatidylinositol 3-Kinases PIK3CA protein, human EGFR protein, human ErbB Receptors
PMC4151469
24453288
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer
2014